School of Life Sciences, The University of Nottingham, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK.
Mol Neurobiol. 2024 Sep;61(9):6968-6983. doi: 10.1007/s12035-024-03987-y. Epub 2024 Feb 16.
The pathogenesis of schizophrenia begins in early neurodevelopment and leads to excitatory-inhibitory imbalance. It is therefore essential that preclinical models used to understand disease, select drug targets and evaluate novel therapeutics encompass similar neurochemical deficits. One approach to improved preclinical modelling incorporates dual-hit neurodevelopmental insults, like neonatal administration of phencyclidine (PCP, to disrupt development of glutamatergic circuitry) then post-weaning isolation (Iso, to mimic adolescent social stress). We recently showed that male Lister-hooded rats exposed to PCP-Iso exhibit reduced hippocampal expression of the GABA interneuron marker calbindin. The current study expanded on this by investigating changes to additional populations of GABAergic interneurons in frontal cortical and hippocampal tissue from the same animals (by immunohistochemistry) as well as levels of GABA itself (via ELISA). Because inflammatory changes are also implicated in schizophrenia, we performed additional immunohistochemical evaluations of Iba-1 positive microglia as well as ELISA analysis of IL-6 in the same brain regions. Single-hit isolation-reared and dual-hit PCP-Iso rats both showed reduced parvalbumin immunoreactivity in the prelimbic/infralimbic region of the frontal cortex. However, this was more widespread in PCP-Iso, extending to the medial/ventral and lateral/dorsolateral orbitofrontal cortices. Loss of GABAergic markers was accompanied by increased microglial activation in the medial/ventral orbitofrontal cortices of PCP-Iso, together with frontal cortical IL-6 elevations not seen following single-hit isolation rearing. These findings enhance the face validity of PCP-Iso, and we advocate the use of this preclinical model for future evaluation of novel therapeutics-especially those designed to normalise excitatory-inhibitory imbalance or reduce neuroinflammation.
精神分裂症的发病机制始于早期神经发育,并导致兴奋性-抑制性失衡。因此,用于了解疾病、选择药物靶点和评估新疗法的临床前模型必须包含类似的神经化学缺陷。一种改进临床前模型的方法是双重神经发育损伤,如新生期给予苯环己哌啶(PCP,破坏谷氨酸能回路的发育),然后断奶后隔离(Iso,模拟青春期社会应激)。我们最近表明,接受 PCP-Iso 暴露的 Lister-hooded 大鼠表现出海马 CA2/3 区 GABA 能中间神经元标志物 calbindin 表达减少。本研究通过对来自同一动物的额皮质和海马组织中的其他 GABA 能中间神经元群体(通过免疫组织化学)以及 GABA 本身(通过 ELISA)的变化进行了扩展。由于炎症变化也与精神分裂症有关,我们还对相同脑区中 Iba-1 阳性小胶质细胞的额外免疫组织化学评估以及 IL-6 的 ELISA 分析进行了研究。单一打击隔离饲养和双重打击 PCP-Iso 大鼠在前额皮质的额前/额下区均显示出明显的 GABA 能中间神经元减少。然而,PCP-Iso 中的这种情况更为广泛,延伸至内侧/腹侧和外侧/背外侧眶额皮质。GABA 能标志物的丢失伴随着内侧/腹侧眶额皮质中小胶质细胞激活的增加,而在单一打击隔离饲养后未见这种情况。这些发现增强了 PCP-Iso 的表面效度,我们主张将这种临床前模型用于未来对新型疗法的评估,特别是那些旨在使兴奋性-抑制性失衡正常化或减少神经炎症的疗法。